Novel Medical Countermeasures for Opioid Intoxication
Award amount
$167,351Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- Department of Defense
- Branch
- Office for Chemical and Biological Defense
- Recipient company
- Clear Scientific, LLC
- Proposal award date
- 2020-04-03
- Contract end date
- 2020-09-03
- UEI
- USCME5Z4GVN7
- Solicitation number
- 19.2
- Topic code
- CBD192-008
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and Xylazine
- Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial
- Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial
- An oral therapeutic to treat intoxication by prescription and illicit stimulants
- Dual Formulation of Atropine/Scopolamine with Enhanced Stability
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection
- Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection
- Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection
Research funding history
19 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $10,849,675. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, Department of Health and Human Services